489 related articles for article (PubMed ID: 22350287)
1. Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris.
Nguyen TT; Woo HJ; Kang HK; Nguyen VD; Kim YM; Kim DW; Ahn SA; Xia Y; Kim D
Biotechnol Lett; 2012 May; 34(5):831-8. PubMed ID: 22350287
[TBL] [Abstract][Full Text] [Related]
2. Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmation.
Nguyen TT; Ryu HJ; Lee SH; Hwang S; Breton V; Rhee JH; Kim D
Bioorg Med Chem Lett; 2011 May; 21(10):3088-91. PubMed ID: 21470860
[TBL] [Abstract][Full Text] [Related]
3. Anti-SARS coronavirus 3C-like protease effects of Rheum palmatum L. extracts.
Luo W; Su X; Gong S; Qin Y; Liu W; Li J; Yu H; Xu Q
Biosci Trends; 2009 Aug; 3(4):124-6. PubMed ID: 20103835
[TBL] [Abstract][Full Text] [Related]
4. Enzymatic activity characterization of SARS coronavirus 3C-like protease by fluorescence resonance energy transfer technique.
Chen S; Chen LL; Luo HB; Sun T; Chen J; Ye F; Cai JH; Shen JK; Shen X; Jiang HL
Acta Pharmacol Sin; 2005 Jan; 26(1):99-106. PubMed ID: 15659121
[TBL] [Abstract][Full Text] [Related]
5. Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS.
Tomar S; Johnston ML; St John SE; Osswald HL; Nyalapatla PR; Paul LN; Ghosh AK; Denison MR; Mesecar AD
J Biol Chem; 2015 Aug; 290(32):19403-22. PubMed ID: 26055715
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies.
Tsai KC; Chen SY; Liang PH; Lu IL; Mahindroo N; Hsieh HP; Chao YS; Liu L; Liu D; Lien W; Lin TH; Wu SY
J Med Chem; 2006 Jun; 49(12):3485-95. PubMed ID: 16759091
[TBL] [Abstract][Full Text] [Related]
7. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.
Chen L; Gui C; Luo X; Yang Q; Günther S; Scandella E; Drosten C; Bai D; He X; Ludewig B; Chen J; Luo H; Yang Y; Yang Y; Zou J; Thiel V; Chen K; Shen J; Shen X; Jiang H
J Virol; 2005 Jun; 79(11):7095-103. PubMed ID: 15890949
[TBL] [Abstract][Full Text] [Related]
8. A mechanistic view of enzyme inhibition and peptide hydrolysis in the active site of the SARS-CoV 3C-like peptidase.
Yin J; Niu C; Cherney MM; Zhang J; Huitema C; Eltis LD; Vederas JC; James MN
J Mol Biol; 2007 Aug; 371(4):1060-74. PubMed ID: 17599357
[TBL] [Abstract][Full Text] [Related]
9. Maturation mechanism of severe acute respiratory syndrome (SARS) coronavirus 3C-like proteinase.
Li C; Qi Y; Teng X; Yang Z; Wei P; Zhang C; Tan L; Zhou L; Liu Y; Lai L
J Biol Chem; 2010 Sep; 285(36):28134-40. PubMed ID: 20489209
[TBL] [Abstract][Full Text] [Related]
10. Discovering severe acute respiratory syndrome coronavirus 3CL protease inhibitors: virtual screening, surface plasmon resonance, and fluorescence resonance energy transfer assays.
Chen L; Chen S; Gui C; Shen J; Shen X; Jiang H
J Biomol Screen; 2006 Dec; 11(8):915-21. PubMed ID: 17092912
[TBL] [Abstract][Full Text] [Related]
11. Autoprocessing mechanism of severe acute respiratory syndrome coronavirus 3C-like protease (SARS-CoV 3CLpro) from its polyproteins.
Muramatsu T; Kim YT; Nishii W; Terada T; Shirouzu M; Yokoyama S
FEBS J; 2013 May; 280(9):2002-13. PubMed ID: 23452147
[TBL] [Abstract][Full Text] [Related]
12. Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition.
Ryu YB; Jeong HJ; Kim JH; Kim YM; Park JY; Kim D; Nguyen TT; Park SJ; Chang JS; Park KH; Rho MC; Lee WS
Bioorg Med Chem; 2010 Nov; 18(22):7940-7. PubMed ID: 20934345
[TBL] [Abstract][Full Text] [Related]
13. Binding interaction of quercetin-3-beta-galactoside and its synthetic derivatives with SARS-CoV 3CL(pro): structure-activity relationship studies reveal salient pharmacophore features.
Chen L; Li J; Luo C; Liu H; Xu W; Chen G; Liew OW; Zhu W; Puah CM; Shen X; Jiang H
Bioorg Med Chem; 2006 Dec; 14(24):8295-306. PubMed ID: 17046271
[TBL] [Abstract][Full Text] [Related]
14. Two adjacent mutations on the dimer interface of SARS coronavirus 3C-like protease cause different conformational changes in crystal structure.
Hu T; Zhang Y; Li L; Wang K; Chen S; Chen J; Ding J; Jiang H; Shen X
Virology; 2009 Jun; 388(2):324-34. PubMed ID: 19409595
[TBL] [Abstract][Full Text] [Related]
15. Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease.
Zhu L; George S; Schmidt MF; Al-Gharabli SI; Rademann J; Hilgenfeld R
Antiviral Res; 2011 Nov; 92(2):204-12. PubMed ID: 21854807
[TBL] [Abstract][Full Text] [Related]
16. Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds.
Lee CC; Kuo CJ; Ko TP; Hsu MF; Tsui YC; Chang SC; Yang S; Chen SJ; Chen HC; Hsu MC; Shih SR; Liang PH; Wang AH
J Biol Chem; 2009 Mar; 284(12):7646-55. PubMed ID: 19144641
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease.
Ramajayam R; Tan KP; Liu HG; Liang PH
Bioorg Med Chem Lett; 2010 Jun; 20(12):3569-72. PubMed ID: 20494577
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease.
Shao YM; Yang WB; Kuo TH; Tsai KC; Lin CH; Yang AS; Liang PH; Wong CH
Bioorg Med Chem; 2008 Apr; 16(8):4652-60. PubMed ID: 18329272
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant.
Akaji K; Konno H; Onozuka M; Makino A; Saito H; Nosaka K
Bioorg Med Chem; 2008 Nov; 16(21):9400-8. PubMed ID: 18845442
[TBL] [Abstract][Full Text] [Related]
20. Mutation of Gly-11 on the dimer interface results in the complete crystallographic dimer dissociation of severe acute respiratory syndrome coronavirus 3C-like protease: crystal structure with molecular dynamics simulations.
Chen S; Hu T; Zhang J; Chen J; Chen K; Ding J; Jiang H; Shen X
J Biol Chem; 2008 Jan; 283(1):554-564. PubMed ID: 17977841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
